Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.65 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.65 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.48 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5575801 | 1.00 | GPR84 (0.65) | GPR84FFAR1FFAR4CA1CA2 | |
| SCHEMBL13849594 | 1.00 | GPR84 (0.65) | GPR84FFAR1FFAR4CA1CA2 | |
| SCHEMBL20472582 | 1.00 | GPR84 (0.65) | GPR84FFAR1FFAR4CA1CA2 | |
| SCHEMBL5575803 | 1.00 | GPR84 (0.65) | GPR84FFAR1FFAR4CA1CA2 | |
| SCHEMBL4957808 | 1.00 | GPR84 (0.65) | GPR84FFAR1FFAR4CA1CA2 | |
| SCHEMBL15007874 | 1.00 | GPR84 (0.65) | GPR84FFAR1FFAR4CA1CA2 | |
| SCHEMBL3761975 | 1.00 | GPR84 (0.65) | GPR84FFAR1FFAR4CA1CA2 | |
| SCHEMBL34950 | 1.00 | GPR84 (0.65) | GPR84FFAR1FFAR4CA1CA2 | |
| SCHEMBL15007853 | 1.00 | GPR84 (0.65) | GPR84FFAR1FFAR4CA1CA2 | |
| SCHEMBL20472255 | 1.00 | GPR84 (0.65) | GPR84FFAR1FFAR4CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3668494-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | Psomagen, Inc. (US) | 2020-06-24 | — | — | EP | claimed |
| WO-2019036507-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | uBiome, Inc. (US) | 2019-02-21 | — | — | WO | claimed |
| CN-119667047-A | Analysis method of polymyxin B sulfate related substances for injection | 海南广升誉制药有限公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250043165-A1 | LOW-TEMPERATURE CURING COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2025-02-06 | — | — | US | disclosed |
| US-20240294780-A1 | ELECTRODEPOSITABLE COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2024-09-05 | — | — | US | disclosed |
| EP-4363511-A1 | ELECTRODEPOSITABLE COATING COMPOSITIONS | PPG Industries Ohio Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-3580290-B1 | LOW-TEMPERATURE CURING COATING COMPOSITIONS | PPG IND OHIO INC (US) | 2024-05-01 | — | — | EP | disclosed |
| US-11952514-B2 | Low-temperature curing adhesive compositions | PPG INDUSTRIES OHIO, INC. (US) | 2024-04-09 | — | — | US | disclosed |
| WO-2023279087-A1 | ELECTRODEPOSITABLE COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2023-01-05 | — | — | WO | disclosed |
| EP-3945820-A1 | USE OF SPECIFIC HYPERBRANCHED COPOLYMERS TO ENHANCE ANTIMICROBIAL ACTION OF ANTIMICROBIAL AGENTS | DSM IP Assets B.V. (NL) | 2022-02-09 | — | — | EP | disclosed |
| EP-3946248-A1 | COMPOSITION COMPRISING SPECIFIC HYPERBRANCHED COPOLYMERS AND 1,3-PROPANDIOL AND/OR N-HYDROXYOCTANAMIDE | DSM IP Assets B.V. (NL) | 2022-02-09 | — | — | EP | disclosed |
| US-20190050525-A1 | RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES | PSOMAGEN, INC. | 2019-02-14 | — | — | US | disclosed |
| WO-2018148323-A1 | LOW-TEMPERATURE CURING ADHESIVE COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| WO-2018148306-A1 | LOW-TEMPERATURE CURING COATING COMPOSITIONS | PPG INDUSTRIES OHIO, INC. (US) | 2018-08-16 | — | — | WO | disclosed |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | FMR LLC | 2016-08-04 | — | — | US | disclosed |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | ENVIVO PHARMACEUTICALS, INC. (US) | 2015-03-19 | — | — | US | disclosed |
| CN-104114530-A | Production method for hydroxy-carboxylic acid amide compound, and novel arylboronic acid compound | UNIV NAGOYA NAT UNIV CORP | 2014-10-22 | — | — | CN | disclosed |
| EP-2340042-B1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | TRASLATIONAL CANCER DRUGS PHARMA S L (ES) | 2014-07-23 | — | — | EP | disclosed |
| US-7355074-B2 | Compounds having aromatic rings and side-chain amide-functionality and a method for transporting monovalent anions across biological membranes using the same | THE UNIVERSITY OF MARYLAND (US) | 2008-04-08 | — | — | US | disclosed |
| US-20050009921-A1 | Compounds having aromatic rings and side-chain amide-functionality and a method for transporting monovalent anions across biological membranes using the same | MARYLAND, UNIVERSITY OF | 2005-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009921-A1 | Compounds having aromatic rings and side-chain amide-functionality and a method for transporting monovalent anions across biological membranes using the same | SLC26A3, SLC22A8, SLC43A1 | GPR84 1156/4885FFAR1 1701/4885FFAR4 1931/4885 |
| US-20150080325-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC5, HDAC2 | GPR84 3717/4885FFAR1 4074/4885FFAR4 4300/4885 |
| US-20160222026-A1 | Dibenzo[B,F][1,4]oxazepin-11-yl-N-Hydroxybenzamides as HDAC Inhibitors | HDAC1, HDAC2, HDAC4 | GPR84 2971/4885FFAR1 3236/4885FFAR4 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.